Clinical trial
A Study of Ocrelizumab in Participants With Primary Progressive Multiple…
NCT01194570 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT01194570 |
|---|---|
| Title | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis |
| Official title | A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Primary Progressive |
| Intervention type | Drug, Other |
| Interventions | Ocrelizumab, Placebo |
| Enrollment | 735 |
| Start date | Mar 2, 2011 |
| Primary completion | Jul 23, 2015 |
| Completion | Dec 31, 2022 |
| First posted | Sep 3, 2010 |
| Last update posted | Jan 10, 2024 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: